What Is Victoza And How Does It Connect To Addiction Recovery?

Victoza (liraglutide) is a diabetes medication now studied for addiction, since GLP-1 activity may help calm cravings.

Victoza is the brand name for liraglutide, a once-daily injectable medication that belongs to a class of drugs called GLP-1 receptor agonists. It was approved by the FDA in 2010 for people 10 years and older with type 2 diabetes, helping the body manage blood sugar more effectively. Victoza is also approved to reduce the risk of heart attack, stroke, and cardiovascular death in adults who have type 2 diabetes and existing heart disease. Liraglutide is considered an earlier-generation, shorter-acting GLP-1 medication compared with newer drugs like semaglutide, though it works through the same basic hormone pathway. The same active ingredient is also sold at a higher dose under the brand name Saxenda for weight management, while Victoza remains the diabetes-focused version.

Outside of diabetes care, liraglutide has drawn growing interest from addiction researchers. GLP-1 receptors are found not only in the gut and pancreas but also in the brain’s mesolimbic dopamine system, the reward circuitry involved in cravings and compulsive substance use. Early animal studies and a small number of human studies have looked at whether liraglutide might reduce the urge to smoke or drink alcohol, building on the broader theory that GLP-1 signaling can quiet reward-driven behavior. This evidence is still smaller and earlier than what exists for semaglutide, so Victoza is best understood today as a subject of ongoing research rather than a recognized addiction treatment. Any use for cravings or substance use would be off-label and require close medical supervision as part of a larger care plan.

How Does Victoza Work In The Body?

Liraglutide mimics a natural gut hormone called glucagon-like peptide 1, which the body releases after eating. By activating GLP-1 receptors, Victoza slows digestion, increases feelings of fullness, and prompts the pancreas to release insulin more effectively when blood sugar rises. These effects are why the medication was developed and approved for managing type 2 diabetes and for lowering cardiovascular risk in adults who already live with heart disease alongside diabetes.

Beyond digestion and blood sugar, GLP-1 receptors also sit in brain regions tied to motivation, reward, and habit. When liraglutide activates these receptors, preclinical research suggests the brain’s response to rewarding substances, including alcohol and nicotine, may be softened. This shared biology is the reason a medication built for diabetes has become part of a wider conversation about the neuroscience of cravings and addiction.

What Does The Research Say About Addiction Recovery?

Most of the evidence connecting liraglutide to addiction recovery comes from animal studies, which have found that the drug can reduce alcohol-seeking and nicotine-related behaviors in preclinical models. A smaller number of early human studies have explored liraglutide’s effects on smoking cessation and alcohol use, with some encouraging but limited signals. Because these studies are fewer and smaller in scale than the semaglutide research now underway, liraglutide is considered an earlier and less established piece of the GLP-1 and addiction puzzle.

Victoza is not FDA-approved to treat any addiction, and any use for cravings or substance use today would be considered off-label and investigational. At a program like Carrara Treatment, medications like this are viewed as a potential future complement to proven, evidence-based care such as therapy, medical detox, and peer support, never as a replacement for it. Patients considering any off-label use should do so only under close physician supervision. The most commonly reported side effects of liraglutide are gastrointestinal, including nausea, and should be discussed with a care team before starting treatment.

Frequently Asked Questions

Is victoza approved to treat addiction?

No. Victoza is FDA-approved for type 2 diabetes in patients 10 years and older, and for reducing the risk of heart attack, stroke, and cardiovascular death in adults with type 2 diabetes and heart disease. It is not approved to treat alcohol use disorder, nicotine dependence, or any other addiction. Research on liraglutide and cravings is still early and mostly preclinical, so any addiction-related use today would be off-label and should only occur under close medical supervision.

What is the difference between victoza and saxenda?

Victoza and Saxenda both contain the same active ingredient, liraglutide, but they serve different approved purposes and doses. Victoza is approved for type 2 diabetes management and related cardiovascular risk reduction, using a lower daily dose. Saxenda delivers a higher dose of liraglutide and is approved specifically for chronic weight management. Despite sharing one molecule, each brand has its own approved use, dosing schedule, and prescribing guidelines to follow closely.

Could victoza help reduce cravings during recovery?

It might, though the evidence is still early. Animal studies suggest liraglutide can lower alcohol-seeking and nicotine-related behaviors, and a few human studies have examined its effects on smoking cessation and drinking. These findings are promising but come from fewer and smaller studies than research on newer GLP-1 drugs like semaglutide. Victoza remains investigational for addiction, is not FDA-approved for this use, and should never replace counseling or medical detox.